Edwards Lifesciences delivered stronger-than-expected third-quarter growth and lifted its full-year 2026 outlook, led by a sharp rise in mitral and tricuspid therapies. A US$220.2 million impairment charge remains a notable counterpoint to the upbeat operating performance.
